Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Trial Profile

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Apomorphine (Primary) ; Levodopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms AM-IMPAKT
  • Sponsors US WorldMeds
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
    • 18 Jun 2015 Results for secondary endpoints in patients treated in the early morning presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top